Tealwood Asset Management Inc. Purchases Shares of 44,385 Cambrex Corp. (CBM)
Tealwood Asset Management Inc. bought a new position in Cambrex Corp. (NYSE:CBM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 44,385 shares of the company’s stock, valued at approximately $2,296,000.
A number of other institutional investors also recently made changes to their positions in CBM. Bayesian Capital Management LP acquired a new stake in Cambrex Corp. during the first quarter worth $276,000. Aperio Group LLC increased its stake in Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock worth $333,000 after buying an additional 221 shares in the last quarter. Glenmede Trust Co. NA increased its stake in Cambrex Corp. by 15.7% in the first quarter. Glenmede Trust Co. NA now owns 11,888 shares of the company’s stock worth $522,000 after buying an additional 1,612 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Cambrex Corp. by 106.5% in the second quarter. BNP Paribas Arbitrage SA now owns 10,385 shares of the company’s stock worth $537,000 after buying an additional 5,356 shares in the last quarter. Finally, Capstone Asset Management Co. increased its stake in Cambrex Corp. by 11.8% in the second quarter. Capstone Asset Management Co. now owns 13,070 shares of the company’s stock worth $676,000 after buying an additional 1,380 shares in the last quarter. 99.46% of the stock is currently owned by institutional investors and hedge funds.
Shares of Cambrex Corp. (NYSE:CBM) traded down 0.84% during midday trading on Friday, hitting $41.45. 328,710 shares of the stock traded hands. The company has a market capitalization of $1.33 billion, a P/E ratio of 20.96 and a beta of 1.57. Cambrex Corp. has a 1-year low of $29.50 and a 1-year high of $59.41. The stock has a 50 day moving average of $44.82 and a 200 day moving average of $47.83.
Cambrex Corp. (NYSE:CBM) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.59 by $0.09. The company earned $118.22 million during the quarter, compared to the consensus estimate of $114.85 million. Cambrex Corp. had a return on equity of 24.86% and a net margin of 13.97%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. Equities research analysts predict that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.
Separately, Zacks Investment Research downgraded shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, June 29th.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.